BioXcel Therapeutics Inc. (BTAI) |
|
44.2 0.84 (1.94%)
|
10-01 09:45 |
|
Open: |
44.01 |
Pre. Close: |
43.36 |
|
High:
|
44.45 |
Low:
|
43.58 |
|
Volume:
|
52,664 |
Market Cap:
|
1,075M |
|
|
|
|
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The company is headquartered in New Haven, Connecticut and currently employs 18 full-time employees. The firm uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
43.927 - 44.105 |
44.105 - 44.274 |
|
Low:
|
41.409 - 41.601 |
41.601 - 41.784 |
|
Close:
|
43.364 - 43.674 |
43.674 - 43.968 |
|
Technical analysis |
as of: 2020-09-30 4:39:29 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 53.65 One year: 59.17 |
| Support: |
Support1: 38.29 Support2: 31.86 |
| Resistance: |
Resistance1: 45.93 Resistance2: 50.66 |
| Pivot: |
44.94  |
| Moving Average: |
MA(5): 42.86 MA(20): 44.52
MA(100): 47.89 MA(250): 29.39 |
| MACD: |
MACD(12,26): -0.32 Signal(9): -0.16 |
| Stochastic oscillator: |
%K(14,3): 27.40 %D(3): 29.54 |
| RSI: |
RSI(14): 48.76 |
| 52-week: |
High: 71.50 Low: 3.76 Change(%): 631.7 |
| Average Vol(K): |
3-Month: 69633 10-Days: 48648 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.BTAI has closed above bottom band by 37.4%. Bollinger Bands are 30.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 29 Sep 2020
BioXcel Therapeutics (NASDAQ:BTAI) Cut to "Buy" at BidaskClub - MarketBeat
Thu, 24 Sep 2020
BioXcel Therapeutics Target of Unusually Large Options Trading (NASDAQ:BTAI) - MarketBeat
Wed, 23 Sep 2020
BioXcel Therapeutics: Opportunity Emerges During Pandemic While Mental Health Is Being Ignored - Seeking Alpha
Wed, 23 Sep 2020
BioXCel Therapeutics (NASDAQ:BTAI) A Hot Buy That Confuses Analysts - MarketBeat
Fri, 18 Sep 2020
Brokerages Anticipate BioXcel Therapeutics Inc (NASDAQ:BTAI) to Post -$0.80 EPS - MarketBeat
Wed, 09 Sep 2020
BioXcel Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
22 |
| Shares Float (M) |
13 |
|
% Held by Insiders
|
48.51 |
|
% Held by Institutions
|
28.52 |
|
Shares Short (K)
|
2,160 |
|
Shares Short P. Month (K)
|
2,810 |
Stock Financials |
|
EPS
|
-2.940 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
2.620 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-64.4 |
|
Return on Equity (ttm)
|
-136.5 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-2.409 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-43 |
|
Levered Free Cash Flow (M)
|
-23 |
Stock Valuations |
|
PE Ratio
|
-14.86 |
|
PEG Ratio
|
|
|
Price to Book value
|
16.67 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-22.94 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
